Scholarlink

<p>Iron is essential for the production of myocardial energy and proteins critical for metabolism. Iron deficiency is common in patients with heart failure and reduced ejection fraction (HFrEF) and is associated with a poor prognosis. However, whether intravenous iron replacement reduces the risk of adverse clinical events in HFrEF patients remains uncertain, despite several outcome trials being conducted. Furthermore, significant uncertainties persist in this setting regarding the most appropriate definition of iron deficiency and the optimal dosing regimen. Here, we critically discuss the findings of the recently published FAIR-HF2 (Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure) trial, which investigated the efficacy and safety of ferric carboxymaltose in patients with HF and iron deficiency, while positioning these results within the broader context of current evidence on intravenous iron supplementation in patients with HFrEF.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Iron repletion in heart failure: a symptomatic win, a survival miss

  • 期刊论文

  • 发表日期：

    2025年5月31日

查看全文
  • Luca Monzo,
  • Baljash Cheema,
  • Andrew P Ambrosy,
  • Nicolas Girerd

摘要

Iron is essential for the production of myocardial energy and proteins critical for metabolism. Iron deficiency is common in patients with heart failure and reduced ejection fraction (HFrEF) and is associated with a poor prognosis. However, whether intravenous iron replacement reduces the risk of adverse clinical events in HFrEF patients remains uncertain, despite several outcome trials being conducted. Furthermore, significant uncertainties persist in this setting regarding the most appropriate definition of iron deficiency and the optimal dosing regimen. Here, we critically discuss the findings of the recently published FAIR-HF2 (Ferric Carboxymaltose Assessment of Morbidity and Mortality in Patients with Iron Deficiency and Chronic Heart Failure) trial, which investigated the efficacy and safety of ferric carboxymaltose in patients with HF and iron deficiency, while positioning these results within the broader context of current evidence on intravenous iron supplementation in patients with HFrEF.